Market Access News | pharmaphorum

News

Statements from HHS suggest new hurdles could be coming for seasonal COVID formulations, though the picture is still unclear.

News

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

News

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the Trump administration.

News

AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with a short-acting successor to its blockbuster Botox brand.

News

MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.

News

Roche is petitioning the US administration for an exemption from tariffs for pharmaceuticals, arguing there is no trade imbalance in its US business.